Sagimet Biosciences (SGMT) Cash from Investing Activities (2022 - 2026)

Sagimet Biosciences' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $10.2 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 199.33% year-over-year to $10.2 million in Q1 2026; TTM through Mar 2026 was $11.4 million, a 118.54% increase from a year earlier, with the FY2025 full-year figure at $4.6 million, up 107.39% from the prior year.
• Cash from Investing Activities fell to $10.2 million in Q1 2026 per SGMT's latest filing, from $14.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $19.4 million in Q1 2023 and bottomed at -$75.2 million in Q2 2024.
• The 5-year median for Cash from Investing Activities is $3.7 million (2022), against an average of -$1.8 million.
• Across the five-year window, Cash from Investing Activities plunged 687.16% in 2024 and jumped 199.33% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at $5.4 million in 2022, then tumbled by 460.93% to -$19.6 million in 2023, then soared by 150.2% to $9.8 million in 2024, then surged by 45.77% to $14.4 million in 2025, then fell by 28.85% to $10.2 million in 2026.
• Per Business Quant, the three latest SGMT Cash from Investing Activities figures stand at $10.2 million (Q1 2026), $14.4 million (Q4 2025), and $75000.0 (Q3 2025).